Research programme: antivirals - Arisyn Therapeutics

Drug Profile

Research programme: antivirals - Arisyn Therapeutics

Alternative Names: ATI-0409; ATI-0607; ATI-0655; ATI-0810; ATI-5488; PG 301209; PG-301995

Latest Information Update: 11 May 2015

Price : $50

At a glance

  • Originator Procter & Gamble
  • Developer Arisyn Therapeutics
  • Class Small molecules
  • Mechanism of Action Hepatitis B virus replication inhibitors; Hepatitis C virus replication inhibitors; HIV replication inhibitors; RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C; Herpes simplex virus infections; HIV infections; Influenza virus infections

Most Recent Events

  • 15 Sep 2009 Pharmacodynamics data from in vitro studies in Hepatitis C presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
  • 14 May 2009 Pharmacodynamics data from a preclinical trial of ATI 0810 in Hepatitis C released by ImQuest and Arisyn
  • 24 Nov 2008 Compounds from this programme are available for licensing (http://www.arisyn.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top